Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AngioDynamics, Inc. AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes September 19, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024 September 19, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces CE Mark Approval in Europe for the Auryon System September 03, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Participate in Upcoming Investor Conferences July 29, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results July 16, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024 July 08, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System May 21, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions May 06, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture April 04, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE April 04, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc. April 01, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024 March 19, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference March 06, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million February 15, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease January 23, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance January 05, 2024 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Present at the J.P. Morgan Healthcare Conference December 21, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024 December 07, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism December 07, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance October 04, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023 September 12, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation August 15, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Completes Enrollment for PRESERVE Clinical Study August 03, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference July 31, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors July 24, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance July 12, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023 June 20, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million June 08, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics to Present at the Needham Virtual Healthcare Conference April 11, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance March 30, 2023 From AngioDynamics, Inc. Via Business Wire Tickers ANGO Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.